TY  - JOUR
AU  - Bergua, Juan M
AU  - Montesinos, Pau
AU  - Martinez-Cuadron, David
AU  - Fernandez-Abellan, Pascual
AU  - Serrano, Josefina
AU  - Sayas, Maria J
AU  - Prieto-Fernandez, Julio
AU  - Garcia, Raimundo
AU  - Garcia-Huerta, Ana J
AU  - Barrios, Manuel
AU  - Benavente, Celina
AU  - Perez-Encinas, Manuel
AU  - Simiele, Adriana
AU  - Rodriguez-Macias, Gabriela
AU  - Herrera-Puente, Pilar
AU  - Rodriguez-Veiga, Rebeca
AU  - Martinez-Sanchez, Maria P
AU  - Amador-Barciela, Maria L
AU  - Riaza-Grau, Rosalia
AU  - Sanz, Miguel A
PY  - 2016
DO  - 10.1111/bjh.14107
UR  - http://hdl.handle.net/10668/10029
T2  - British journal of haematology
AB  - The combination of fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor (FLAG-Ida) is widely used in relapsed/refractory acute myeloid leukaemia (AML). We retrospectively analysed the results of 259 adult AML patients treated...
LA  - en
PB  - John Wiley & Sons
KW  - FLAG-Ida
KW  - Genetic risk
KW  - Prognostic factors
KW  - Relapsed-refractory acute myeloid leukaemia
KW  - Salvage treatment
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Allografts
KW  - Aminoglycosides
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Cytarabine
KW  - Gemtuzumab
KW  - Granulocyte Colony-Stimulating Factor
KW  - Hematopoietic Stem Cell Transplantation
KW  - Humans
KW  - Idarubicin
KW  - Leukemia, Myeloid, Acute
KW  - Middle Aged
KW  - Prognosis
KW  - Remission Induction
KW  - Retrospective Studies
KW  - Risk Assessment
KW  - Salvage Therapy
KW  - Survival Analysis
KW  - Vidarabine
KW  - Young Adult
TI  - A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.
TY  - research article
VL  - 174
ER  -